A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Conditions: Lymphoma, Non-Hodgkin; Hodgkin Disease Interventions: Drug: Relatlimab; Drug: Nivolumab Sponsor: Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials